Novavax, Inc. (NVAX) is up 28.58% today after receiving $1.6 billion from the U.S. government to accelerate its development of a COVID-19 vaccine. This funding is for Operation Warp Speed that Norobax was selected to participate in along with other biotech companies with the focus of the program aimed at delivering a safe, effective, and readily available COVID-19 vaccine by 2021. Noravax was awarded funding for its COVID-19 treatment candidate, NVX?CoV2373. The candidate is currently in late stage clinical testing with Noravax expecting to be able to deliver over 100 million doses by the end of 2020 if the vaccine passes its remaining clinical trials.
NVAX stock is up 1955.33% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary scoring system, gives NVAX stock a score of 67 out of a possible 100.
That score is chiefly influenced by a long-term technical score of 99. NVAX’s score also includes a short-term technical score of 98. The fundamental score for NVAX is 3. In addition to the average rating from Wall Street analysts, NVAX stock has a mean target price of 66.333. This means analysts expect the stock to decline 35.06% over the next 12 months.
What’s Happening with NVAX Stock Today
Novavax, Inc. (NVAX) stock has gained 28.58% while the S&P 500 is lower by -0.1% as of 10:52 AM on Tuesday, Jul 7. NVAX is up $22.70 from the previous closing price of $79.44 on volume of 12,701,483 shares. Over the past year the S&P 500 is up 6.74% while NVAX is up 1955.33%. NVAX lost -$4.14 per share in the over the last 12 months.
